{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T19:16:34Z","timestamp":1771010194833,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"7","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.autrev.2012.08.013","type":"journal-article","created":{"date-parts":[[2012,8,23]],"date-time":"2012-08-23T16:46:00Z","timestamp":1345740360000},"page":"691-693","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Can we reduce the dosage of biologics in spondyloarthritis?"],"prefix":"10.1016","volume":"12","author":[{"given":"Ignazio","family":"Olivieri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"D'Angelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Padula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Leccese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Nigro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Palazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2012.08.013_bb0005","first-page":"85","article-title":"Crit\u00e8res de classification des spondylarthropathies","volume":"57","author":"Amor","year":"1990","journal-title":"Rev Rhum Mal Osteoartic"},{"key":"10.1016\/j.autrev.2012.08.013_bb0010","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/art.1780341003","article-title":"The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy","volume":"34","author":"Dougados","year":"1991","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2012.08.013_bb0015","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","article-title":"Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial","volume":"48","author":"Davis","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2012.08.013_bb0020","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2012.08.013_bb0025","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2012.08.013_bb0030","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2012.08.013_bb0035","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2012.08.013_bb0040","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1136\/ard.2005.045658","article-title":"The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1year","volume":"65","author":"Kavanaugh","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2012.08.013_bb0045","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2012.08.013_bb0050","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/art.24403","article-title":"Golimumab, a new human tumor necrosis factor \u03b1 antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study","volume":"60","author":"Kavanaugh","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.autrev.2012.08.013_bb0055","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.autrev.2011.04.012","article-title":"Role of the complement system in rheumatoid arthritis and psoriatic arthritis: relationship with anti-TNF inhibitors review article","volume":"10","author":"Ballanti","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2012.08.013_bb0060","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nrrheum.2009.258","article-title":"Disease modification in ankylosing spondylitis","volume":"6","author":"Maksymowych","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2012.08.013_bb0065","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/art.23260","article-title":"Critical appraisal of assessment of structural damage in ankylosing spondylitis: implication for treatment outcomes","volume":"58","author":"Sieper","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2012.08.013_bb0070","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.autrev.2012.05.009","article-title":"Biologic registries in rheumatology: lessons learned and expectations for the future","volume":"12","author":"Elkayam","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"Suppl. 2","key":"10.1016\/j.autrev.2012.08.013_bb0075","first-page":"S126","article-title":"Clinical and radiographic outcomes of four different strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized controlled study","volume":"58","author":"Goekoop-Ruiteman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2012.08.013_bb0080","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/ard.2009.121491","article-title":"Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis, RRR (remission induction by Remicade in RA) study","volume":"69","author":"Tanaka","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2012.08.013_bb0085","doi-asserted-by":"crossref","first-page":"R439","DOI":"10.1186\/ar1693","article-title":"Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3years of continuous treatment with infliximab","volume":"7","author":"Baraliakos","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2012.08.013_bb0090","first-page":"510","article-title":"Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis","volume":"34","author":"Baraliakos","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2012.08.013_bb0095","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/art.11017","article-title":"Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis","volume":"48","author":"Brandt","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2012.08.013_bb0100","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/rheumatology\/keh475","article-title":"Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis","volume":"44","author":"Brandt","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2012.08.013_bb0105","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s10067-011-1722-5","article-title":"Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease","volume":"30","author":"Navarro-Comp\u00e1n","year":"2011","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2012.08.013_bb0110","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s10067-010-1542-z","article-title":"Extended dosing of etanercept 25 mg can be effective in patients with ankylosing spondylitis: a retrospective analysis","volume":"29","author":"Lee","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2012.08.013_bb0115","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2012.08.013_bb0120","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1002\/art.23606","article-title":"Efficacy of adalimumab in the treatment of axial spondyloarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two","volume":"58","author":"Haibel","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2012.08.013_bb0125","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/art.24408","article-title":"Clinical and imaging efficacy of infliximab in HLA-B27-positive patients with magnetic resonance imaging-determined early sacroiliitis","volume":"60","author":"Barkham","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2012.08.013_bb0130","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/ard.2010.139667","article-title":"Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial","volume":"70","author":"Song","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2012.08.013_bb0135","series-title":"Presented at the 2011 ACR\/ARPH Annual Meeting. Chicago, IL USA","article-title":"Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis\u2014results from a phase 3 study","author":"Sieper","year":"2011"},{"key":"10.1016\/j.autrev.2012.08.013_bb0140","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1136\/annrheumdis-2011-201010","article-title":"Frequency and duration of drug-free remission after 1year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2year data of the ESTHER trial","volume":"71","author":"Song","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2012.08.013_bb0145","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2010.133645","article-title":"The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general","volume":"70","author":"Rudwaleit","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2012.08.013_bb0150","first-page":"118","article-title":"Successful treatment of severe undifferentiated spondyloarthropathy with anti-tumor necrosis factor \u03b1 monoclonal antibody infliximab","volume":"29","author":"Brandt","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2012.08.013_bb0155","first-page":"531","article-title":"Successful treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor \u03b1 receptor fusion protein etanercept","volume":"31","author":"Brandt","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2012.08.013_bb0160","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1136\/ard.2009.121533","article-title":"A randomized, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial","volume":"69","author":"Dougados","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2012.08.013_bb0165","first-page":"39","article-title":"Pharmacologic management of undifferentiated spondyloarthropathies","volume":"15","author":"Palazzi","year":"2006","journal-title":"Exp Opin Rheumatol"},{"key":"10.1016\/j.autrev.2012.08.013_bb0170","first-page":"1057","article-title":"A brief course of anti-TNF-\u03b1 therapy can cure recurrent episodes of HLA-B27-associated severe and refractory heel enthesitis","volume":"27","author":"Olivieri","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2012.08.013_bb0175","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1002\/art.23096","article-title":"Switching TNF\u03b1 inhibitors may also be useful in HLA-B27-associated severe heel enthesitis","volume":"57","author":"Olivieri","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2012.08.013_bb0180","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1093\/rheumatology\/kel208","article-title":"Successful treatment of juvenile onset HLA-B27 associated severe and refractory heel enthesitis with adalimumab","volume":"45","author":"Olivieri","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2012.08.013_bb0185","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.autrev.2011.04.015","article-title":"Anti-TNF\u03b1 discontinuation in rheumatoid and psoriatic arthritis: is it possible after disease remission?","volume":"10","author":"Chimenti","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2012.08.013_bb0190","first-page":"1045","article-title":"Remission in psoriatic arthritis","volume":"28","author":"Gladman","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2012.08.013_bb0195","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1093\/rheumatology\/keg384","article-title":"A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience","volume":"42","author":"Kane","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2012.08.013_bb0200","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1002\/art.1780241012","article-title":"Preliminary criteria for clinical remission in rheumatoid arthritis","volume":"24","author":"Pinals","year":"1981","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2012.08.013_bb0205","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1093\/rheumatology\/ken059","article-title":"Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs","volume":"47","author":"Cantini","year":"2008","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2012.08.013_bb0210","doi-asserted-by":"crossref","first-page":"R94","DOI":"10.1186\/ar3021","article-title":"Remission in psoriatic arthritis: is it possible and how can it be predicted?","volume":"12","author":"Saber","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2012.08.013_bb0215","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3111\/13696998.2010.487469","article-title":"Etanercept treatment patterns in managed-care patients with psoriasis or psoriatic arthritis","volume":"13","author":"Thayer","year":"2010","journal-title":"J Med Econ"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997212001929?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997212001929?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,21]],"date-time":"2018-11-21T03:33:55Z","timestamp":1542771235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997212001929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S1568997212001929"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2012.08.013","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can we reduce the dosage of biologics in spondyloarthritis?","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2012.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}